Workshop

20 November 2019-Wednesday, 16:15-18:30: Workshop for Drug Development-Risk Assessment through Data Analytics

Time

Workshop- Wednesday, 20 November 2019

Room

Wednesday, 16:15-18:30

Workshop for Drug Development-Risk Assessment through Data Analytics

Jehangir Hall

The Risk Assessment on drug development workshop is an interactive course directed towards participants who wish to update their understanding of global regulations, the translational sciences and drug development.  Efficiency and Quality compliance are critical to achieve innovation and affordability. This comprehensive course will provide an overview of the basics and multi-dimensional nature of drug development utilizing technology, statistical and quality considerations.  The workshop will focus on development of novel drugs, including recombinant proteins, monoclonal antibodies, fusion proteins, cell therapy, gene therapy and gene editing technologies

1.      Dr Narendra Chirmule, Chief Scientific Advisor, Immuneel Therapeutics Ltd; ex-Head of R&D at Biocon

2.      Dr Robert Poolman, Director of Discovery and Preclinical Products, Clarivate Analytics

3.      Dr Timea Gombos MD, PhD, Director Translational Sciences and Biostatistics, Accelsiors, Hungary

4.      Dr Guljit Chaudhri, MD, Bioinnovat Ltd., CEO, Innonation / Sr. Advisor, ABLE